Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | -0.08 | 0.03 |
| FCF Yield | -80.80% | -294.93% | -53.55% | -73.23% |
| EV / EBITDA | -1.08 | 25.36 | -0.28 | 0.82 |
| Quality | ||||
| ROIC | -89.82% | -65.95% | -103.03% | -47.84% |
| Gross Margin | 93.76% | 98.67% | 90.37% | -2,839.81% |
| Cash Conversion Ratio | 0.83 | 5.70 | 0.56 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.40% | 145.69% | – | – |
| Free Cash Flow Growth | -3.02% | -96.45% | 4.18% | -24.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 33.01 | 0.86 | 2.06 |
| Interest Coverage | -7.78 | -10.57 | -37.54 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.80 | 4.42 | -0.16 | -8.04 |
| Cash Conversion Cycle | -255.33 | -4,615.41 | -2,994.86 | 288.31 |